APP and Alzheimer disease: Collectively, these findings suggest that reduced hsa-miR-20a-5p expression contributes to increased APP levels, while the downregulation of hsa-miR-185-5p and hsa-miR-181c-5p leads to upregulation of their respective targets, facilitating Aβ accumulation and plaque formation in AD pathology [165].